A phase II/III trial of epitinib in first-line patients with EGFR-mutant NSCLC patients with brain metastasis
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 18 Aug 2016
At a glance
- Drugs Epitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 18 Aug 2016 New trial record
- 02 Aug 2016 According to Chi-Med media release, company targets to initiate this pivotal registration study before the end of H1 2017.
- 02 Aug 2016 According to a Chi-Med media release, China FDA has granted clinical trial application clearance for this trial in July 2016.